Your Search for adverse reaction or adverse event or side effect matched 1000 Documents (Page 1 of 34).
You may want to refine your search. Results Indexed by relevance.
Abstract: The MHRA and the Commission on Human Medicines (CHM) run the UK’s spontaneous adverse drug reaction reporting scheme - called the Yellow Card Scheme. This receives reports of suspected adverse drug reactions (ADRs) from healthcare professionals. More recently the scheme was extended to included direct reporting by pati ...
http://www.aegis.org/pubs/i-base/2007/ib070811-13.html
File Name: ib070811-13.html, Size: 8KB, Last Modified: Thursday, May 21, 2009 at 9:28:48 PM
Abstract: In Treatment Review #31 we reported on bone damage as a possible side effect of anti-HIV protease inhibitors . More information has now been reported in the scientific journal AIDS. Researchers from St. Louis studied 112 men receiving protease inhibitors. These men had been taking protease inhibitors for an average of ...
http://www.aegis.org/pubs/atdn/2000/tr000902.html
File Name: tr000902.html, Size: 8KB, Last Modified: Thursday, May 21, 2009 at 9:27:01 PM
Abstract: In Information Bulletin #8, we reported on bone damage as a possible side effect of anti-HIV protease inhibitors . More information has now been reported in the scientific journal AIDS. Researchers from St. Louis studied 112 men receiving protease inhibitors. These men had been taking protease inhibitors for an average ...
http://www.aegis.org/pubs/atdn/2000/tr000601.html
File Name: tr000601.html, Size: 7KB, Last Modified: Thursday, May 21, 2009 at 9:27:01 PM
Abstract: Specialist nurses providing PLA treatment for HIV facial lipoatrophy have comparable rates of adverse events to a plastic surgeon SpR. This is a useful measure of safety that will enable services to expand nurses’ roles to decrease waiting lists and reduce staffing costs. ...
http://www.aegis.org/conferences/bhiva/2007/p53.html
File Name: p53.html, Size: 6KB, Last Modified: Thursday, March 29, 2007 at 8:12:04 PM
Abstract: I started HIV therapy last year, when my T-cells were at 19 and my VL was >500.000. In the past few months I've got some ugly swollen veins in my arms and legs and I'm losing fat from my cheeks.... ...
http://www.aegis.org/askdoc/askd030108.html
File Name: askd030108.html, Size: 6KB, Last Modified: Tuesday, March 06, 2007 at 7:14:58 PM
Abstract: New side effect ...
http://www.aegis.org/pubs/catie/1997/cate7907.html
File Name: cate7907.html, Size: 8KB, Last Modified: Tuesday, March 06, 2007 at 6:43:28 PM
Abstract: Kaletra, formerly known as ABT-378, is the brand name of two protease inhibitors packaged together C ritonavir (Norvir) and lopinavir. ...
http://www.aegis.org/news/catie/2001/cate-n20010507.html
File Name: cate-n20010507.html, Size: 7KB, Last Modified: Monday, January 08, 2007 at 11:20:10 PM
Abstract: Complete info about Epzicom & treatment for HIV & AIDS. ...
http://www.aegis.org/factshts/network/simple/stav.html
File Name: stav.html, Size: 7KB, Last Modified: Friday, October 27, 2006 at 6:27:52 AM
Abstract: What is Pancreatitis? HIV drugs that can cause Pancreatitis, symptoms, risk of experiencing pancreatitis, diagnosis, treatment ...
http://www.aegis.org/factshts/network/simple/panc.html
File Name: panc.html, Size: 7KB, Last Modified: Sunday, August 20, 2006 at 9:21:21 PM
Abstract: What is Myopathy, Cardiomyopathy, Myositis? HIV drugs that can cause Myopathy, Cardiomyopathy, Myositis, symptoms, risk of experiencing, diagnosis, treatment ...
http://www.aegis.org/factshts/network/simple/myop.html
File Name: myop.html, Size: 9KB, Last Modified: Sunday, August 20, 2006 at 9:21:18 PM
Abstract: What is Lactic Acidosis and Hepatic Steatosis? HIV drugs that can cause Lactic Acidosis and Hepatic Steatosis, symptoms, risk of experiencing Lactic Acidosis and Hepatic Steatosis, diagnosis, treatment ...
http://www.aegis.org/factshts/network/simple/lactic.html
File Name: lactic.html, Size: 9KB, Last Modified: Sunday, August 20, 2006 at 9:21:15 PM
Abstract: In this population, severe anaemia was uncommon among adults starting ART. Individuals with lower haemoglobin at time of starting ART had a higher risk of a haemoglobin adverse event. However, amongst individuals with haemoglobin at 6 months, lower haemoglobin at ART start was associated with a greater median increase ...
http://www.aegis.org/conferences/iashivpt/2005/tupe11-8c06.html
File Name: tupe11-8c06.html, Size: 9KB, Last Modified: Monday, July 25, 2005 at 6:29:23 AM
Abstract: Multiexperienced patients that receive combination therapy that include d4T+ddI rarely develop severe drug-related toxicity. As in the preHAART era, CD4 count is the main factor associated with toxicity. ...
http://www.aegis.org/conferences/iashivpt/2005/tupe2-4c04.html
File Name: tupe2-4c04.html, Size: 8KB, Last Modified: Monday, July 25, 2005 at 6:29:23 AM
Abstract: On review of 783 HIV-infected pediatric patients, there was one case of fulminant hepatitis similar to that seen in adults, which was reported in a 17-year-old. There was no evidence of a serious clinical hepatic event associated with NVP use in any child prior to adolescence. The reason for this is unclear and may be ...
http://www.aegis.org/conferences/croi/2005/776.html
File Name: 776.html, Size: 8KB, Last Modified: Tuesday, February 22, 2005 at 8:12:04 PM
Abstract: An adapted objective lipodystrophy case definition was more sensitive for diagnosing lipodystrophy in Gilead 903 than unprompted adverse event reports. ...
http://www.aegis.org/conferences/lipo/2004/11.html
File Name: 11.html, Size: 5KB, Last Modified: Tuesday, October 26, 2004 at 6:29:23 AM
Abstract: OBJECTIVE: To evaluate the treatment outcome amongst HIV 1 positive patients with a combination of ART drugs under the protocol given by CDC, Atlanta. Design: The study population comprised of 150 patients admitted in the AIDS clinic run by MMHRC. Prior to treatment, the clinical history, personal particulars. 10 ml of ...
http://www.aegis.org/conferences/iac/2004/b10173.html
File Name: b10173.html, Size: 6KB, Last Modified: Monday, July 12, 2004 at 6:29:23 AM
Abstract: Objectives: Evaluate the safety and tolerability of ddI/TDF in ARV for HIV-infected adults in the HOPS cohort. METHODS: Subjects identified using an electronic database of patients at 9 US clinics who received >14 days of ddI/TDF prior to Oct 2003. Adverse events that were examined in this analysis were ...
http://www.aegis.org/conferences/iac/2004/wepeb5922.html
File Name: wepeb5922.html, Size: 6KB, Last Modified: Monday, July 12, 2004 at 6:29:23 AM
Abstract: BACKGROUND: In clinical practice it seems that the tolerability, the incidence of side effects and the reason for discontinuation of NNRTIs could be higher than described in the literature. METHODS: Retrospective cohort study. An accurate chart review was conducted to evaluate the onset of any side effect related to tr ...
http://www.aegis.org/conferences/iac/2004/b10704.html
File Name: b10704.html, Size: 6KB, Last Modified: Monday, July 12, 2004 at 6:29:23 AM
Abstract: Multiple hepatic adverse events were reported to AERS, primarily in patients receiving NRTI and/or NVP. The majority were reported in patients receiving ARV commonly prescribed during pregnancy (ZDV, 3TC, NVP). The most commonly reported adverse events were increased transaminases and conditions associated with pregnan ...
http://www.aegis.org/conferences/croi/2004/944.html
File Name: 944.html, Size: 8KB, Last Modified: Sunday, February 08, 2004 at 8:12:04 PM
Abstract: AEGIS, 8th EUROPEAN CONFERENCE ON CLINIC ASPECTS AND TREATMENT OF HIV - INFECTION. Abstract Form. REFERENCE NUMBER : 143. ECCATH ID : P360. 8th EUROPEAN CONFERENCE ON CLINIC ASPECTS AND TREATMENT OF HIV - INFECTION. Location of research or project (country). France.. Thematic Areas:. 12. EPIDEMIOLOGY/COHORT STUDIES. ...
http://www.aegis.org/conferences/eacs/2001/posters/317.html
File Name: 317.html, Size: 10KB, Last Modified: Monday, December 29, 2003 at 10:30:27 PM
Abstract: <p><b>BACKGROUND:</b> IDV combined with RTV 100 mg bid is usually prescribed at the dose of 800 mg bid but recent pharmacokinetic (PK) data (1,2) have shown that IDV 400 mg bid presents a good PK profile and provides a better tolerance. </p> <p><b>METHODS:</b> To compare the efficacy and tolerability of IDV 800 mg b ...
http://www.aegis.org/conferences/iac/2002/tupeb4456.html
File Name: tupeb4456.html, Size: 7KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
Abstract: WASHINGTON (Reuters) - Pregnant women may face a higher risk of a potentially fatal side effect from an HIV-fighting drug combi ...
http://www.aegis.org/news/re/2001/re010105.html
File Name: re010105.html, Size: 7KB, Last Modified: Friday, January 05, 2001 at 4:02:00 AM
Abstract: A French study confirms recent reports of hair loss in men as a side effect of the protease inhibitor Crixivan ( Indinavir ). All ten men in the study experienced various types of hair ...
http://www.aegis.org/aidsline/2000/sep/a0090306.html
File Name: a0090306.html, Size: 8KB, Last Modified: Thursday, September 28, 2000 at 8:12:04 PM
Abstract: RATIONALE AND OBJECTIVES: A delayed adverse reaction is one occurring more than an hour after injection of contrast media. ...
http://www.aegis.org/pubs/medline/1998/jan/m9819446.html
File Name: m9819446.html, Size: 5KB, Last Modified: Saturday, January 31, 1998 at 10:00:00 PM
Abstract: PURPOSE: Drug therapies for patients with human immunodeficiency virus (HIV) infection are associated with adverse events that can potentially limit their effectiveness. We sought to quantify the incidence of these events in clinical practice and determine whether there were demographic and clinical differences in adv ...
http://www.aegis.org/aidsline/1996/oct/m96a0481.html
File Name: m96a0481.html, Size: 10KB, Last Modified: Monday, October 28, 1996 at 8:12:04 PM
Abstract: Some authors had previously reported that a combined therapy using AZT+ddI is better than the maintenance of a monotherapy with AZT or ddI. Our study confirms this conclusion and tends to determine the appropriate timefor the switch. Actually the benefit of the association is better for a patient with AZT, when CD-4 ce ...
http://www.aegis.org/conferences/hiv-glasgow/1994/p28.html
File Name: p28.html, Size: 8KB, Last Modified: Friday, November 18, 1994 at 8:12:04 PM
Abstract: If you are experiencing any changes in vision you should see an ophthalmologist who is knowledgeable about HIV-related conditio ...
http://www.aegis.org/pubs/atdn/1994/atr01101.html
File Name: atr01101.html, Size: 5KB, Last Modified: Sunday, May 01, 1994 at 11:00:00 PM
Abstract: OBJECTIVE: To evaluate the long term effects of zidovudine (ZDV) in HIV seropositive men. METHODS: 74 HIV seropositive men (CDC groups II, III or IVC2 and CD4 greater than 270) were enrolled in a 3 centre prospective study between January and May 1987. ZDV was initially administered in increasing doses to 1200 mg dail ...
http://www.aegis.org/aidsline/1991/dec/m91c1944.html
File Name: m91c1944.html, Size: 9KB, Last Modified: Saturday, December 28, 1991 at 8:12:04 PM
Abstract: <p><b>OBJECTIVE</b>: To evaluate the long term effects of zidovudine (ZDV) in HIV seropositive men.</p> <p><b>METHODS</b>: 74 HIV seropositive men (CDC groups II, III or IVC2 and CD4 greater than 270) were enrolled in a 3 centre prospective study between January and May 1987. ZDV was initially administered in increa ...
http://www.aegis.org/conferences/iac/1991/wb2099.html
File Name: wb2099.html, Size: 6KB, Last Modified: Sunday, June 16, 1991 at 8:12:04 PM
Abstract: The use of the protease inhibitor nelfinavir (Viracept) has been associated with diarrhea. Some community-based clinics report that upwards of 80% of their clients who are using nelfinavir experience this side effect to varying degrees. While this figure is higher than what has been reported in studies, it underscores ...
http://www.aegis.org/pubs/projinform/2003/pi030116.html
File Name: pi030116.html, Size: 8KB, Last Modified: Thursday, May 21, 2009 at 9:30:31 PM